CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
nicotinamidedrug
Likely dose
nicotinamide 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03419364
NCT03419364Phase 2Completed
CompareCT.gov

Phase II Study of Nicotinamide in Early Onset Preeclampsia

University of North Carolina, Chapel Hill·interventional·Posted Feb 1, 2018·Updated Sep 8, 2022

In Brief

A Phase 2 clinical trial evaluating nicotinamide for Pre-Eclampsia and Pregnancy Related. Completed, enrolled 23 participants across 1 site.

Detailed Summary

Phase II Study of 2.5 gm of nicotinamide, given daily in 3 divided doses, to measure effect on maternal blood pressure in women with early onset preeclampsia and to determine peak and trough levels of nicotinamide. We will compare peak and trough levels in healthy non-pregnant and healthy pregnant participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPre-Eclampsia, Pregnancy Related
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 1, 2018
Enrollment StartNov 1, 2017
Primary CompletionAug 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.4 years ago

Interventions

nicotinamidedrug

2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday